---
title: "Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in HER2-Positive"
id: "journal-of-clinical-oncology-23-neoadjuvant-taxane-plus-trastuzumab-and-pertuzumab-with-or-without-carboplatin-in-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-the-randomized-noninferiority-phase-iii-neocarhp-trial"
canonical_url: "https://medichelpline.com/clinical-feed/journal-of-clinical-oncology-23-neoadjuvant-taxane-plus-trastuzumab-and-pertuzumab-with-or-without-carboplatin-in-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-the-randomized-noninferiority-phase-iii-neocarhp-trial"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Journal of Clinical Oncology (JCO)"
source_url: "https://ascopubs.org/doi/abs/10.1200/JCO-25-02176?af=R"
published_at: "2026-01-23T08:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in HER2-Positive
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/journal-of-clinical-oncology-23-neoadjuvant-taxane-plus-trastuzumab-and-pertuzumab-with-or-without-carboplatin-in-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-the-randomized-noninferiority-phase-iii-neocarhp-trial
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Journal of Clinical Oncology (JCO)
- **Source URL:** [Original Journal Publication](https://ascopubs.org/doi/abs/10.1200/JCO-25-02176?af=R)
- **Published At:** 2026-01-23T08:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
Journal of Clinical Oncology (JCO) published a clinical update in Oncology on 23 Jan 2026. The item focuses on Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial. Review the original article for the full source wording and details.
## Clinical Analysis & Structured Key Points
Journal of Clinical Oncology (JCO) published a clinical update in Oncology on 23 Jan 2026. The item focuses on Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial. Review the original article for the full source wording and details.
## Related Clinical Research

- [VISTA: Virtual spatial transcriptomics from H&E for prognostic and therapy response prediction in](https://medichelpline.com/clinical-feed/biorxiv-21-virtual-spatial-transcriptomics-from-histopathology-enables-prognostic-and.md)
- [Next-generation Antibody–Drug Conjugates: Strategies to Improve Efficacy and Clinical Development](https://medichelpline.com/clinical-feed/nature-0-the-next-generation-of-antibody-drug-conjugates.md)
- [Chemotherapy-Associated Colitis After TCbHP in HER2-Positive Breast Cancer: Case Report](https://medichelpline.com/clinical-feed/pubmed-42571049.md) (DOI: 10.12659/AJCR.952507)
- [Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer](https://medichelpline.com/clinical-feed/nejm-11-trastuzumab-deruxtecan-in-residual-her2-positive-early-breast-cancer.md)
- [Sympathetic Overdrive, Vascular Dysfunction, and Exercise Intolerance in Long-Term Breast Cancer](https://medichelpline.com/clinical-feed/journal-of-the-american-heart-association-65-sympathetic-neural-overactivation-vascular-dysfunction-and-exercise-intolerance-in-long-term-survivors-of-breast-cancer-treated-with-doxorubicin-and-trastuzumab-based-chemotherapy.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.